

AXIM BIOTECH ATTENDS BIOTECH SHOWCASE AND J.P. MORGAN HEALTHCARE CONFERENCES IN SAN FRANCISCO

NEW YORK – Jan 10, 2017 – AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC: AXIM), a world leader in cannabinoid research and development, today announced that George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM Biotech, is meeting with business prospects and investors at the Biotech Showcase 9th Annual Conference and the J.P. Morgan 35th Annual Healthcare Conference in San Francisco.

Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to meet with investors and pharmaceutical executives at one of the industry's largest annual healthcare investor conferences.

J.P. Morgan Healthcare Conference is the life science industry's leading conferences of the year. It brings thousands of investors and executives from around the world to San Francisco where companies share their latest innovations with business partners and investors.

###

About AXIM

AXIM® Biotechnologies, Inc. (OTC: [AXIM](http://www.AXIMBiotech.com)) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew®, a CBD-based controlled release chewing gum, and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. We prioritize the well-being of our customers while embracing a solid fiscal strategy. Medical Marijuana, Inc. is a major investor in AXIM. For more information, visit www.AXIMBiotech.com.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein.

LEGAL DISCLOSURE

AXIM Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).

Public Relations Contact:

Andrew Hard

Chief Executive Officer

CMW Media

andrew.hard@cmwmedia.com

P. +1888 829-0070

www.cmwmedia.com

Investor Relations Contact

Shiwei Yin, Grayling

Shiwei.Yin@grayling.com

P. +1646 824-2857

Lucia Domville, Grayling

lucia.domville@grayling.com

P. +1646 284-9416

Corporate Contact Info

North American Address:

18 East 50th Street, 5 Floor

New York, NY 10022

+1 844 294 6246

European Address:

Boelewerf 32, Unit 3

2987 VD Ridderkerk, The Netherlands

+31 10 8209 227